ES2621291T3 - Derivados de 3,4,4a,10b-tetrahidro-1h-tiopirano-[4,3-c]isoquinolina - Google Patents
Derivados de 3,4,4a,10b-tetrahidro-1h-tiopirano-[4,3-c]isoquinolina Download PDFInfo
- Publication number
- ES2621291T3 ES2621291T3 ES14164018.5T ES14164018T ES2621291T3 ES 2621291 T3 ES2621291 T3 ES 2621291T3 ES 14164018 T ES14164018 T ES 14164018T ES 2621291 T3 ES2621291 T3 ES 2621291T3
- Authority
- ES
- Spain
- Prior art keywords
- inhibitors
- receptor antagonists
- thiopyran
- tetrahydro
- tetrahydrobiopterin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 title 2
- 239000002464 receptor antagonist Substances 0.000 abstract 2
- 229940044551 receptor antagonist Drugs 0.000 abstract 2
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 abstract 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 abstract 1
- -1 2-ethyl-2H-tetrazol-5-yl Chemical group 0.000 abstract 1
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 abstract 1
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 1
- 229940126062 Compound A Drugs 0.000 abstract 1
- 101710095468 Cyclase Proteins 0.000 abstract 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 abstract 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 1
- 102000003834 Histamine H1 Receptors Human genes 0.000 abstract 1
- 108090000110 Histamine H1 Receptors Proteins 0.000 abstract 1
- 101000959437 Homo sapiens Beta-2 adrenergic receptor Proteins 0.000 abstract 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 abstract 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 abstract 1
- 229930003316 Vitamin D Natural products 0.000 abstract 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract 1
- 239000012190 activator Substances 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 229940127219 anticoagulant drug Drugs 0.000 abstract 1
- 229940124748 beta 2 agonist Drugs 0.000 abstract 1
- 239000002876 beta blocker Substances 0.000 abstract 1
- 229940097320 beta blocking agent Drugs 0.000 abstract 1
- 239000000480 calcium channel blocker Substances 0.000 abstract 1
- 239000000812 cholinergic antagonist Substances 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 229960001334 corticosteroids Drugs 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 229940030606 diuretics Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000002308 endothelin receptor antagonist Substances 0.000 abstract 1
- 229960003444 immunosuppressant agent Drugs 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000002617 leukotrienes Chemical class 0.000 abstract 1
- 239000003580 lung surfactant Substances 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 abstract 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 abstract 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 abstract 1
- 229960003073 pirfenidone Drugs 0.000 abstract 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 abstract 1
- 229960004617 sapropterin Drugs 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 235000019166 vitamin D Nutrition 0.000 abstract 1
- 239000011710 vitamin D Substances 0.000 abstract 1
- 150000003710 vitamin D derivatives Chemical class 0.000 abstract 1
- 229940046008 vitamin d Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09179982 | 2009-12-18 | ||
| EP09179982 | 2009-12-18 | ||
| US31555210P | 2010-03-19 | 2010-03-19 | |
| US315552P | 2010-03-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2621291T3 true ES2621291T3 (es) | 2017-07-03 |
Family
ID=41718903
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14164018.5T Active ES2621291T3 (es) | 2009-12-18 | 2010-12-15 | Derivados de 3,4,4a,10b-tetrahidro-1h-tiopirano-[4,3-c]isoquinolina |
| ES10790569.7T Active ES2505290T3 (es) | 2009-12-18 | 2010-12-15 | Derivados de 3,4,4A,10B-tetrahidro-1H-tiopirano[4,3-c]isoquinolina |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10790569.7T Active ES2505290T3 (es) | 2009-12-18 | 2010-12-15 | Derivados de 3,4,4A,10B-tetrahidro-1H-tiopirano[4,3-c]isoquinolina |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US9018175B2 (enExample) |
| EP (2) | EP2513119B1 (enExample) |
| JP (1) | JP5645961B2 (enExample) |
| KR (1) | KR20120123313A (enExample) |
| CN (1) | CN102652136B (enExample) |
| AR (1) | AR079451A1 (enExample) |
| AU (1) | AU2010332955B8 (enExample) |
| BR (1) | BR112012014058A8 (enExample) |
| CA (1) | CA2784013A1 (enExample) |
| CO (1) | CO6551705A2 (enExample) |
| DK (1) | DK2513119T3 (enExample) |
| EA (1) | EA023212B1 (enExample) |
| ES (2) | ES2621291T3 (enExample) |
| GE (1) | GEP20146105B (enExample) |
| HR (1) | HRP20140893T1 (enExample) |
| ME (1) | ME01914B (enExample) |
| MX (1) | MX2012006696A (enExample) |
| NZ (1) | NZ601115A (enExample) |
| PH (1) | PH12012501125A1 (enExample) |
| PL (1) | PL2513119T3 (enExample) |
| PT (1) | PT2513119E (enExample) |
| RS (1) | RS53544B1 (enExample) |
| SG (2) | SG196785A1 (enExample) |
| SI (1) | SI2513119T1 (enExample) |
| SM (1) | SMT201400185B (enExample) |
| TW (1) | TWI468411B (enExample) |
| UA (1) | UA107689C2 (enExample) |
| WO (1) | WO2011073231A1 (enExample) |
| ZA (1) | ZA201204135B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101930561B1 (ko) | 2010-06-07 | 2018-12-18 | 사푸라스트 리써치 엘엘씨 | 재충전 가능한 고밀도 전기 화학 장치 |
| CA2827045A1 (en) * | 2011-02-17 | 2012-08-23 | Cipla Limited | Compositions of glycopyrrolate and a beta2-agonist |
| US20140113877A1 (en) | 2011-06-15 | 2014-04-24 | Takeda Gmbh | Novel 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c] isoquinoline compounds |
| WO2014016548A2 (en) * | 2012-07-27 | 2014-01-30 | Cipla Limited | Pharmaceutical composition |
| WO2014090990A1 (en) * | 2012-12-13 | 2014-06-19 | Ludwig Aigner | Leukotriene pathway antagonists for the treatment of dementia, cognitive deficits in parkinson's disease and/or learning and memory deficiencies in parkinson's disease |
| WO2014117947A1 (en) | 2013-02-04 | 2014-08-07 | Grünenthal GmbH | 4-amino substituted condensed pyrimidine compounds as pde4 inhibitors |
| AP2015008663A0 (en) | 2013-02-19 | 2015-08-31 | Pfizer | Azabenzimidazole compounds as inhibitors of PDE4 isozymes for the treatment of cns and other disorders |
| EP3172210B1 (en) | 2014-07-24 | 2020-01-15 | Pfizer Inc | Pyrazolopyrimidine compounds |
| SG11201700243YA (en) | 2014-08-06 | 2017-02-27 | Pfizer | Imidazopyridazine compounds |
| WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
| WO2022006470A1 (en) | 2020-07-01 | 2022-01-06 | Vanderbilt University | Methods of treatment for a kidney disease |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3899494A (en) | 1970-05-13 | 1975-08-12 | Sandoz Ltd | Substituted 6-phenyl benzo-naphthyridines |
| DE2047465A1 (de) | 1970-09-26 | 1972-03-30 | Farbwerke Hoechst AG, vorm Meister Lucius & Bruning, 6000 Frankfurt | Neue Oxdiazole und Verfahren zu lh rer Herstellung |
| CN1003445B (zh) | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物，其制备方法和用途 |
| JPH01213284A (ja) | 1988-02-22 | 1989-08-28 | Sankyo Co Ltd | チエノピリミジン−２，４−ジオン誘導体 |
| GB8828477D0 (en) | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
| ES2060040T5 (es) | 1989-05-31 | 1999-09-16 | Fisons Plc | Dispositivo y formulacion de inhalacion de medicamento. |
| GB8921222D0 (en) | 1989-09-20 | 1989-11-08 | Riker Laboratories Inc | Medicinal aerosol formulations |
| IE67185B1 (en) | 1990-02-02 | 1996-03-06 | Fisons Plc | Propellant compositions |
| DE4003272A1 (de) | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen |
| CA2077354A1 (en) | 1990-03-23 | 1991-09-24 | Minnesota Mining And Manufacturing Company | Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations |
| AU658854B2 (en) | 1990-10-18 | 1995-05-04 | Minnesota Mining And Manufacturing Company | Aerosol formulation comprising beclomethasone 17,21 dipropionate |
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| IL104068A (en) | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant |
| GB9213874D0 (en) | 1992-06-30 | 1992-08-12 | Fisons Plc | Process to novel medicament form |
| GB9306703D0 (en) | 1993-03-31 | 1993-05-26 | Fisons Plc | Inhalation device |
| IL111194A (en) | 1993-10-08 | 1998-02-08 | Fisons Plc | Process for the production of medicament formulations |
| GEP20012390B (en) | 1996-11-11 | 2001-03-25 | Byk Gulden Lomberg Chem Fab | Benzonaphthyridines as Bronchial Therapeutics |
| ES2179490T3 (es) | 1997-05-08 | 2003-01-16 | Merck Sharp & Dohme | Derivados de 1,2,4-triazolo(3,4-a)ftalazina sustituidos como ligandos de gaba alfa 5. |
| AU8106598A (en) | 1997-06-03 | 1998-12-21 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Benzonaphthyridine |
| EP1102579B1 (de) | 1998-08-04 | 2003-03-19 | Jago Research Ag | Medizinische aerosolformulierungen |
| US6397838B1 (en) | 1998-12-23 | 2002-06-04 | Battelle Pulmonary Therapeutics, Inc. | Pulmonary aerosol delivery device and method |
| DE60024992T2 (de) | 1999-04-23 | 2006-08-24 | Battelle Memorial Institute, Columbus | Richtungsverstellbarer ehd- aerosol-zerstäuber |
| KR20020005721A (ko) | 1999-04-23 | 2002-01-17 | 추후기재 | 하이 매스 전달 전기분무기 |
| CN1414951A (zh) | 1999-10-28 | 2003-04-30 | 基本治疗公司 | 药剂排出泵抑制药 |
| AU2001281802A1 (en) | 2000-06-07 | 2001-12-17 | Almirall Prodesfarma, S.A. | 6-phenylpyrrolopyrimidinedione derivatives |
| AU2001281965A1 (en) | 2000-07-14 | 2002-01-30 | Byk Gulden Lomberg Chemische Fabrik G.M.B.H. | Novel 6-phenylphenanthridines |
| ATE320242T1 (de) | 2000-10-09 | 2006-04-15 | 3M Innovative Properties Co | Medizinische aerosolzusammensetzung |
| CA2462200A1 (en) | 2001-08-10 | 2003-02-20 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
| US20030216407A1 (en) | 2002-01-31 | 2003-11-20 | Pfizer Inc. | Use of PDE5 inhibitors in the treatment of scarring |
| GB0202254D0 (en) | 2002-01-31 | 2002-03-20 | Pfizer Ltd | Prevention of scarring |
| AU2003253165A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
| WO2005102317A1 (en) | 2004-04-23 | 2005-11-03 | Celgene Corporation | Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension |
| WO2006027345A2 (en) * | 2004-09-08 | 2006-03-16 | Altana Pharma Ag | Novel 3-thia-10-aza-phenanthrene derivatives |
| JP5009799B2 (ja) * | 2004-09-08 | 2012-08-22 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規の３−オキサ−１０−アザ−フェナントレン |
| JP4943858B2 (ja) | 2004-11-17 | 2012-05-30 | キッセイ薬品工業株式会社 | 芳香族アミド誘導体、それを含有する医薬組成物およびそれらの医薬用途 |
| WO2006095009A1 (en) | 2005-03-09 | 2006-09-14 | Nycomed Gmbh | Amido-substituted 6-phenylphenanthridines |
| CA2684644A1 (en) * | 2007-04-23 | 2008-10-30 | Sanofi-Aventis | Quinoline-carboxamide derivatives as p2y12 antagonists |
| US20140113877A1 (en) * | 2011-06-15 | 2014-04-24 | Takeda Gmbh | Novel 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c] isoquinoline compounds |
-
2010
- 2010-12-14 AR ARP100104617A patent/AR079451A1/es unknown
- 2010-12-15 ME MEP-2014-114A patent/ME01914B/me unknown
- 2010-12-15 WO PCT/EP2010/069704 patent/WO2011073231A1/en not_active Ceased
- 2010-12-15 NZ NZ601115A patent/NZ601115A/en not_active IP Right Cessation
- 2010-12-15 AU AU2010332955A patent/AU2010332955B8/en not_active Ceased
- 2010-12-15 SG SG2014000335A patent/SG196785A1/en unknown
- 2010-12-15 US US13/515,214 patent/US9018175B2/en not_active Expired - Fee Related
- 2010-12-15 PT PT107905697T patent/PT2513119E/pt unknown
- 2010-12-15 ES ES14164018.5T patent/ES2621291T3/es active Active
- 2010-12-15 SG SG2012034732A patent/SG180824A1/en unknown
- 2010-12-15 HR HRP20140893AT patent/HRP20140893T1/hr unknown
- 2010-12-15 PL PL10790569T patent/PL2513119T3/pl unknown
- 2010-12-15 CA CA2784013A patent/CA2784013A1/en not_active Abandoned
- 2010-12-15 EP EP10790569.7A patent/EP2513119B1/en active Active
- 2010-12-15 SI SI201030746T patent/SI2513119T1/sl unknown
- 2010-12-15 PH PH1/2012/501125A patent/PH12012501125A1/en unknown
- 2010-12-15 UA UAA201208482A patent/UA107689C2/ru unknown
- 2010-12-15 DK DK10790569.7T patent/DK2513119T3/da active
- 2010-12-15 GE GEAP201012783A patent/GEP20146105B/en unknown
- 2010-12-15 KR KR1020127017957A patent/KR20120123313A/ko not_active Withdrawn
- 2010-12-15 CN CN201080057293.7A patent/CN102652136B/zh not_active Expired - Fee Related
- 2010-12-15 RS RSP20140499 patent/RS53544B1/sr unknown
- 2010-12-15 EP EP14164018.5A patent/EP2813509B1/en active Active
- 2010-12-15 EA EA201200891A patent/EA023212B1/ru not_active IP Right Cessation
- 2010-12-15 BR BR112012014058A patent/BR112012014058A8/pt not_active IP Right Cessation
- 2010-12-15 MX MX2012006696A patent/MX2012006696A/es active IP Right Grant
- 2010-12-15 JP JP2012543701A patent/JP5645961B2/ja not_active Expired - Fee Related
- 2010-12-15 ES ES10790569.7T patent/ES2505290T3/es active Active
- 2010-12-17 TW TW99144591A patent/TWI468411B/zh not_active IP Right Cessation
-
2012
- 2012-05-24 CO CO12085785A patent/CO6551705A2/es active IP Right Grant
- 2012-06-06 ZA ZA2012/04135A patent/ZA201204135B/en unknown
-
2014
- 2014-12-11 SM SM201400185T patent/SMT201400185B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023003098A1 (es) | Formas amorfas en estado sólido útiles como inhibidores de kras g12c | |
| WO2009118759A3 (en) | Heterocyclic compounds as adenosine receptor antagonist | |
| PE20081341A1 (es) | Inhibidores de la actividad de la akt | |
| GEP201706774B (en) | Heterocyclyl compounds | |
| RU2006125720A (ru) | Пиперидинаминобензимидазольные производные как ингибиторы репликации респираторного синцитиального вируса | |
| HRP20171999T1 (hr) | Novi derivati aminopirimidina | |
| HRP20240161T1 (hr) | Inhibitor atr i njegova primjena | |
| EA201591239A1 (ru) | Замещенные фталазин-1(2h)-оновые производные в качестве селективных ингибиторов поли(адф-рибоза)полимеразы-1 | |
| JP2011522866A5 (enExample) | ||
| WO2015058163A3 (en) | Heteromaromatic compounds useful for the treatment of prolferative diseases | |
| MX381053B (es) | Formas cristalinas de las sales del compuesto 5-(((1r,1as,6br)-1-(6-(trifluorometil)-1h-benzo[d]imidazol-2-il)-1a,6b-dihidro-1h-ciclopropa [b] benzofuran-5-il) oxi)-3,4-dihidro-1,8-naftiridin-2(1h)-ona, sus métodos de preparación sus usos de las mismas. | |
| PH12013500773A1 (en) | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts | |
| HRP20201727T1 (hr) | 2-((5-(1-(3-(metilsulfonil)propil)piperidin-4-il)piridin-2-il)amino)pirido[2,3-d]pirimidin-7(8h)-on derivati i srodni spojevi kao cdk4 inhibitori za liječenje tumora | |
| NZ597533A (en) | Apoptosis signal-regulating kinase inhibitors | |
| HRP20221207T1 (hr) | Supstituirani biciklički heterociklički spojevi kao inhibitori prmt5 | |
| NO20082121L (no) | Imidazopyridinderivater som A2B-adenosinreseptorantagonister | |
| RU2011100786A (ru) | Производные имидазопиридина в качестве ингибиторов рецепторных тирозинкиназ | |
| FI2501384T4 (fi) | Menetelmä bcr-abl-, c-kit-, ddr1-, ddr2- tai pdgf-r-kinaasiaktiivisuuden välittämien proliferatiivisten häiriöiden ja muiden patologisten tilojen hoitamiseksi | |
| JP2017512803A5 (enExample) | ||
| NZ712802A (en) | Novel n-acyl-(3-substituted)-(8-substituted)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders | |
| CL2012001221A1 (es) | Compuestos derivados de 4 -(1h-pirrol-1-il) pirimidin -2-ilamino y 4 -(1h-pirazol-1-il)- pirimidin-2-ilamino, inhibidores de quinasa; un compuesto isomerico; composicion farmaceutica; utiles en el tratamiento del asma, enfermedad pulmonar obstructiva cronica, colitis ulcerante, enfermedad de crohn, bronquitis, dermatitis, entre otras. | |
| PE20140234A1 (es) | Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1 | |
| IN2014CN04174A (enExample) | ||
| WO2011121418A9 (en) | 4 - aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists | |
| MX368157B (es) | Formulaciones de sal de meglumina del acido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxilico. |